TransCode Therapeutics (RNAZ)

• Market cap: $7.35M
• 1 day: 3.62%
• 5 days: -3.37%
• 1 month: -10.49%
• 3 months: -19.56%
• 6 months: -16.2%
• Year to date: 8.38%
• 1 year: -32.21%
• 5 years: -100%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Employees: 12